Ipa's lensai™ platform delivers x-ray–level epitope mapping insights in hours, matching gold-standard methods with greater speed

Austin, texas--(business wire)---- $amd #ai--immunoprecise antibodies ltd. (ipa) (nasdaq:ipa) a leader in ai-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping application, part of the lensai™ platform, with a direct comparison to gold-standard wet-lab methods. the results represent a notable advancement in computational biology, particularly in the field of antibody discovery, where high failure rates and cos.
AMD Ratings Summary
AMD Quant Ranking